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Introduction
Hepatocellular carcinoma (HCC) presents the most common primary liver tumor and third most common cause of cancer related death worldwide (1) . Tumor angiogenesis is required for HCC development, enabling the distinction of dysplastic and tumor nodules by contrast enhanced imaging (2) and providing the rationale for antiangiogenic therapy of advanced stage disease, e.g. with the receptor tyrosine kinase inhibitor sorafenib and transarterial chemoembolization (TACE) (3) .
Unsatisfactory preclinical modeling of HCC and the lack of robust tools for the assessment of treatment response beyond the evaluation of tumor burden (4) have hampered progress in testing and validating new tumor therapies (5) .
Preclinical HCC model systems, in particular genetically engineered mouse models (GEMMS), have been invaluable tools for the molecular dissection of human hepatocarcinogenesis to date (6) .
However, translational research requires model systems that recapitulate the human condition in its complexity. For example, lack of an underlying liver damage, a frequent accompanying condition in human HCC, presents an important shortcoming of several preclinical model systems (7) . As a consequence preclinical therapy trials conducted on aberrantly, e.g. subcutaneously located tumors, showing outstanding drug efficacy, failed to translate into clinical efficacy most likely due to a nonphysiological simplicity of the model system with clonal origin of the tumor, lack of tumor matrix, an insufficient subcutaneous blood supply and sometimes lack of a functioning immune response (8, 9) .
Considering the clinical significance of TACE treatment in advanced stage HCC, model systems should furthermore provide the possibility for combinatorial treatment testing, for example testing of combinations of TACE and targeted therapies, which is technically difficult to achieve in mouse models. The diethylnitrosamine (DEN) induced rat HCC model system was first introduced in the early 1960s, exhibiting multifocal HCC in a chronically damaged liver background. In contrast, the multifocal orthotopical implantation model is a frequently employed alternative, where tumors develop within a healthy liver after portal vein injection of tumor cells.
Quantitative assessment of HCC physiology and therapy response is challenging, both in vivo and ex Author Manuscript Published OnlineFirst on ; DOI: 10.1158/1078-0432.CCR- and therapy response (10) . The aim of this study was to further implement a multimodal multiparametric imaging platform in the more complex multifocal McA and DEN rat HCC model systems and to compare quantitative imaging, histological and genetic data for potential differences in liver and tumor physiology.
Materials and Methods
Animal models and imaging protocol. All animal experiments were approved and performed in accordance with the institutional animal care and use committee's guidelines and the government of Bavaria, Germany. As depicted in Supplementary Figure S1A , chemically induced tumors (DEN) were established in 24 seven-week old male Wistar rats (Charles River, Sulzfeld, Germany) by oral feeding of 0.01% diethylnitrosamine (DEN, Sigma, Germany) dissolved in drinking water for a period of 8 weeks. Orthotopically implanted multifocal HCC (McA) was generated in 7 six-week old Buffalo rats (Harlan, Horst, Netherlands) by portal vein infusion of 10 7 syngeneic McA-RH7777 cells (American Type Culture Collection, Manassas, VA) as a 1 ml suspension of serum-free DMEM as previously described (11) . Magnetic resonance imaging (MRI) was performed using a 1. Wiesbaden, Germany) and monitored by continuous recording of the electrocardiogram (ECG) and rectal temperature (SA Instruments Inc., NY, USA).
Sorafenib therapy. In a second cohort, 23 DEN-induced and 7 orthotopically implanted animals bearing tumor nodules ≥ 5 mm were treated with the multi-kinase inhibitor sorafenib (Nexavar, Bayer) or vehicle every other day (0.1mg / kg redissolved in DMSO, i.p.). Tumor response was monitored longitudinally by T2w-, DCE-and DWI-MRI on day -1, 0, 1, 7 and 14 ( Supplementary Fig. S1B ).
After final imaging, rats were kept under anaesthesia and euthanized. Tumors were processed for histological analyses.
Data analysis and statistics. Tumor volume (V) was manually segmented and calculated from the T 2 w data sets (Osirix, http://www.osirix.com). Paired and unpaired t-test and tumor growth kinetics estimation were performed using Prism Graphpad 4 (California, USA). DCE-MRI and DWI data were analyzed using in-house software written in IDL (ITT VIS, Boulder, CO, USA) as previously described (10) DCE-MRI data were analyzed semi-quantitatively by calculating tumor-to-muscle and liver-to-muscle ratios of the area under the Gd-DTPA concentration time curves of the first 60 seconds (AUGC60) after contrast agent injection. 3D volumes of interest (VOI) of fused PET-MRI images were analyzed using the absolute mean value of the tumor 3D VOI and normalized to two 2D spinal muscle ROIs in order to calculate the mean tumor-to-muscle and liver-to-muscle ratios. Hilden, Germany). Genomic DNA was extracted and purified according to the manufacturer's protocol followed by quantification with the Nanodrop spectrophotometer. The DNA from 4 to 5 strain-specific healthy livers was pooled and used as reference DNA. For each array 250 ng of reference DNA was labeled with Cy5 and the same amount of sample DNA was labeled with Cy3 using an oligo array CGH labeling kit (Enzo). The labeled DNA was purified using Microcon YM-50 columns (Millipore) and hybridized on custom designed whole genome rat CGH 8 x 60k arrays (Agilent) according to the manufacturer's protocol.
Array CGH data analysis and visualization. After washing and scanning according to the manufacturer's protocol the resulting data text files were subjected to preprocessing, normalization and copy number calling within the statistical platform R (www.R-project.org). Spatial normalization was conducted using the Bioconductor package MANOR (15) and the copy number status of each array probe was called using the CGHcall package (16) followed by complexity reduction using the CGHregions package (17).
In order to visually assess the copy number profiles, karyogram-like plots were generated along rat ideogrammes using an in-house written function. PCA plots based on the probe-wise probability values for normal copy numbers were generated using the ggbiplot package (https://github.com/vqv/ggbiplot) in order to visually assess global differences copy number profiles.
The copy number status of the Flt1 (Vegfr) and Vegfa genes were visualized using the levelplot function from the lattice package (http://cran.r-project.org/web/packages/lattice/index.html).
Comparability of genomic copy number changes detected in our animal model with that occurring in human cryptogenic HCC as published in a study by Schlaeger et al. (18) we conducted a synteny analysis between rat and human as described in Wolf et al. (19) . The analysis was visualized using functions from the CRAN package RCircos. Array CGH data has been deposited at the ArrayExpress repository (accession number: E-MTAB-3507). Fig. S2A ) reflected chronic liver damage of DEN treated animals. In contrast, the architecture of McA liver tissue was unchanged and showed a normal sinusoidal structure without matrix deposition (Fig. 1B and D) . Liver function as determined by serum enzyme levels was altered with aspartate aminotransferase (ASAT) and alanine aminotransferase (12) levels significantly elevated prior to tumor development, beginning at 4 weeks and further increasing at 8 weeks of DEN treatment, indicating hepatocellular dysfunction ( Fig. 1E and F) . Endpoint gamma-glutamyl transpeptidase (GGT) serum levels were not significantly changed (Fig. 1G) . The cholinesterase (ChE), a marker of liver synthesis, was reduced in both models (Fig. 1H) . (Fig. 2D) . Tumor proliferation was also assessed by FLT-PET; however uptake was overall low and no significant difference was detected between the two model systems (1.2±0.2 and 1.3±0.2).
Results

Research
Heterogeneity was further confirmed by array comparative genomic hybridization (aCGH) analyses.
aCGH revealed chromosomal aberrations in all HCCs ( Fig. 2E and F Response to anti-angiogenic treatment. The detected differences in tumor perfusion were of particular interest because of its role in current treatment regimen based on anti-angiogenic agents or TACE. AUGC60 ratios were higher in DEN animals compared to McA animals (5.07±2.34 and 1.96±0.92, p=0.0047) (Fig. 5A) . This difference was also evident in quantitative histological analyses of CD31 expression, which revealed a significantly larger mean vascular lumen area in DEN compared to McA tumors (2.05 % ± 0.22 versus 0.37 % ± 0.15, p < 0.0001) (Fig. 5B and C) . The detected difference in vascularity was accompanied by less spontaneous necrosis in DEN compared to
McA tumors (0.13 % ± 0.35 versus 8.53 % ± 5.01, p < 0.0001) (Fig. 5D ). No differences were noted with regard to caspase-3 expression (data not shown). To further test the physiological significance of this finding with regard to vascular targeting therapies, DEN (n=12) and McA (n=4) tumor bearing animals were subjected to sorafenib treatment. Interestingly, DEN tumors only showed reduced AUGC60 ratios (Fig. 6A) and tumor volume growth kinetics in the treatment compared to the placebo group (Fig. 6C) , whereas sorafenib treatment induced no change in McA tumors (Fig. 6B and D) . The (20) , (7, 21) . We chose the DEN model because of its genetic similarity to human HCC (22) . Furthermore, previous reports described the development of HCC in DEN fed animals within a chronically damaged liver background, similar to the human scenario (23) . On the other hand, orthotopically transplanted rat HCC is considered a valuable time-and cost-efficient model system, widely employed in preclinical drug efficacy studies (24), (25) . The differences in tumor physiology detected between the two models likely reflect a mixture of local (i.e. tumoral) and systemic (i.e. strain) physiology. A comparison of genomic copy number alterations detected in the applied animal models with that occurring in a human array CGH data set on cryptogenic HCCs ( Supplementary Fig.   S3B -E) (18) by synteny analysis showed the majority of copy number alterations present in both data sets.
Research. Liver damage. Biochemical liver function tests and histological analyses confirm previous reports of a chronic toxic liver damage in the DEN model system. Tissue damage was classified as mild to moderate fibrosis rather than cirrhosis. Furthermore, increased FDG uptake, increased hepatocyte proliferation and the presence of inflammatory cells also indicated an earlier stage of chronic liver damage compared to previous reports. Increased liver to muscle AUGC60 values in addition suggest an pro-angiogenic response as recently reported in the CCl4 and bile duct ligation models (26) .
Similarly, an arterialization of the regular sinusoidal blood supply is described for progressive liver disease in pre-cirrhotic human subjects (27). The confirmation of chronic liver damage in the DEN model has important implications with regard to imaging as well as drug efficacy studies. First, sensitivity and specificity and thus the value of a particular imaging technique depend on the tumor-tobackground contrast that can be achieved with the particular technique. Especially in heterotopic model systems these are often artificially high (e.g. subcutaneous tumor implants). Secondly, a compromised liver function presents a major obstacle in clinical therapy trials, which are often jeopardized by increased drug toxicity (28) .
Tumor heterogeneity. In our study we noted a large amount of intra-and inter-tumoral variability in the DEN model. Tumor heterogeneity is a characteristic feature of several cancer types, including HCC (29, 30) . It presents a significant barrier to effective therapy development and thus is of particular importance in preclinical drug efficacy studies. Quantitative assessment of this heterogeneity in HCC physiology by non-invasive imaging has been proposed (31, 32) but presents a major challenge in clinical routine, due to motion artifacts and insufficient spatial resolution in abdominal imaging. Several studies are now beginning to address this issue with documented intraand inter-subject variability in several biomarkers, including FDG uptake, as well as DWI-and DCE-MRI parameters (33, 34) S4 ). These differences in perfusion related parameters are of particular importance for several reasons.
A high level of tumor perfusion provides the rationale for anti-angiogenic and TACE treatment in human HCC and thus should be reflected in a preclinical model system. Furthermore, variability in tumor perfusion has also been described for human HCC, where it correlates with tumor grading, thus presenting a potential biomarker of histopathological grading (35) We still have a limited understanding of the mechanism of action of sorafenib in advanced stage HCC.
Sorafenib targets tyrosine kinases including BRAF, the vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR) and thus inhibit multiple kinases that may be active in HCC. In the DEN model, 20% of the tumor nodules exhibit BRAF point-mutations (37) . Accordingly, the effects seen on tumor perfusion and growth kinetics in DEN tumors are not easily dissected and may be attributable to tumor cell toxicity and anti-angiogenic action.
Pikarsky´s group recently identified a VEGF based paracrine activation loop between tumor cells and tumor macrophages (38) . Despite Vegfa amplification in McA tumors, blockage thereof failed to control tumor growth, possibly due to the lack of macrophage recruitment in this model system as shown immunohistochemically (Supplementary Fig. 2A ).
Limitations. Different rat strains were employed in the DEN and McA model, presenting a potential limitation. However, differences in tumor perfusion were confirmed by histological findings.
Sorafenib treatment in the McA model was limited to one week, and had to be discontinued due to 
